Cargando…
Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective
Novel coronavirus disease 2019 (COVID-19) is caused by a nonsegmented positive sense RNA, enveloped RNA virus that belongs to the family of β-coronaviridae. This virus shall cause acute respiratory distress syndrome (ARDS) which consequently leads to breathing difficulty and need to admit to intensi...
Autor principal: | Khodavirdipour, Amir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110359/ https://www.ncbi.nlm.nih.gov/pubmed/33987628 http://dx.doi.org/10.1055/s-0041-1726461 |
Ejemplares similares
-
Cephalexin: clinical and laboratory studies.
por: Lyons, R. W., et al.
Publicado: (1971) -
Cephalexin Induced Cholestatic Jaundice
por: Agrawal, Abhinav, et al.
Publicado: (2014) -
Cephalexin-Induced Leukocytoclastic Vasculitis
por: Tang, Wesley, et al.
Publicado: (2022) -
Cephalexin-induced acute generalized exanthematous pustulosis
por: DaCunha, Matthew, et al.
Publicado: (2018) -
1506. Outcomes of Standardized Neonatal Cephalexin Dosing
por: Robertson, Melena J, et al.
Publicado: (2019)